What is the half-life of Tirzepatide?

Tirzepatide has a half-life of ~5 days, which is why it's typically administered Once weekly for optimal therapeutic effect.

How do I reconstitute Tirzepatide?

Add bacteriostatic water to the peptide vial slowly down the side. Typical reconstitution uses 2-3ml of water for a 5mg vial. Gently swirl, do not shake.

Growth Hormone

Approved

Tirzepatide

Also known as: Mounjaro, Zepbound, LY3298176

Overview

Key Facts

Primary Goal: A first-in-class dual GIP and GLP-1 receptor agonist that has demonstrated superior weight loss compared to other incretin-based therapies

A first-in-class dual GIP and GLP-1 receptor agonist that has demonstrated superior weight loss compared to other incretin-based therapies. Tirzepatide uniquely targets both incretin pathways, producing remarkable results in clinical trials for obesity and type 2 diabetes. Half-Life ~5 days Typical Dose 2.5–15 mg Frequency Once weekly Cycle Length Ongoing / indefinite under medical supervision

Dosing Information

Half-Life

~5 days

Typical Dose

2.5–15 mg

Frequency

Once weekly

Cycle Length

Ongoing / indefinite under medical supervision

Administration Routes:

subcutaneous

Storage & Reconstitution

Unreconstituted (Powder)

Temperature2–8°C (36–46°F)

DurationUp to 3 months

Reconstituted (Mixed)

Temperature2–8°C (36–46°F)

Duration2-4 weeks

Research Summary

Approved

The SURMOUNT-1 trial showed tirzepatide 15 mg produced an average weight loss of 22.5% over 72 weeks in participants with obesity, with over one-third of participants achieving ≥25% weight loss. SURPASS trials demonstrated HbA1c reductions of up to 2.6% in type 2 diabetes. FDA-approved for both type 2 diabetes (Mounjaro) and chronic weight management (Zepbound).